UNION therapeutics
UNION therapeutics, a pioneering biopharmaceutical company headquartered in Denmark (DK), focuses on developing innovative treatments for dermatological and respiratory diseases. Founded in 2017, UNION therapeutics has quickly established itself in the industry, leveraging its expertise in drug development to address unmet medical needs. The company is renowned for its unique approach to utilising established compounds in novel therapeutic applications, particularly in the field of skin and respiratory health. With a strong emphasis on research and development, UNION therapeutics has achieved significant milestones, including advancing several candidates through clinical trials. Positioned as a leader in the biopharmaceutical sector, UNION therapeutics is committed to improving patient outcomes through its cutting-edge therapies, making a notable impact in the healthcare landscape.
DitchCarbon Score
How does UNION therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
UNION therapeutics's score of 16 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
UNION therapeutics's reported carbon emissions
In 2023, UNION therapeutics reported total carbon emissions of approximately 2,154,000 kg CO2e, with no emissions from Scope 1 and only 2,000 kg CO2e from Scope 2. The majority of their emissions, about 2,152,000 kg CO2e, were attributed to Scope 3, indicating significant reliance on upstream activities. This represents a decrease from 2022, where total emissions were approximately 3,952,000 kg CO2e, with Scope 2 emissions at 17,000 kg CO2e and Scope 3 emissions at about 3,935,000 kg CO2e. In 2021, UNION therapeutics had total emissions of around 4,100,000 kg CO2e, with Scope 1 emissions at 4,100,000 kg CO2e and Scope 3 emissions at approximately 3,852,000 kg CO2e. This data highlights a notable reduction in emissions over the two-year period from 2021 to 2023. Despite these reductions, UNION therapeutics has not publicly committed to specific reduction targets or initiatives, nor have they engaged with the Science Based Targets initiative (SBTi) for formal targets. Their climate commitments remain unspecified, indicating a potential area for future development in their sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 4,100,000 | - | - |
| Scope 2 | - | 00,000 | 0,000 |
| Scope 3 | 3,852,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
UNION therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
